Its safety profile is excellent, effects are well-documented, and benefits extend beyond physical performance
[DOI] [PubMed] 73.Cohen PR
The Core Issue: Failure to Warn Patients of Severe Risks The central argument in the GLP-1 lawsuits is that manufacturers like Novo Nordisk and Eli Lilly knew, or should have known, about the risk of severe side effects like stomach paralysis and bowel obstruction but failed to adequately warn doctors and patients
Trustworthy providers will require a legitimate prescription before dispensing medications to ensure they are appropriate for your treatment
Baseline body weight in STEP 1, STEP 3, and STEP 8 was approximately 105 kg, and slightly lower (approximately 100 kg) in STEP 2, which focused on patients with type 2 diabetes and even lower in STEP 4 (approximately 96 kg), which featured a 20-week run-in where all patients received semaglutide before randomization
24 , 1530 (2016) Cho, Y